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BACKGROUND: Genome-wide association studies have identified 
multiple loci associated with stroke. However, the specific stroke subtypes 
affected, and whether loci influence both ischemic and hemorrhagic 
stroke, remains unknown. For loci associated with stroke, we aimed to 
infer the combination of stroke subtypes likely to be affected, and in 
doing so assess the extent to which such loci have homogeneous effects 
across stroke subtypes.
METHODS: We performed Bayesian multinomial regression in 16 664 
stroke cases and 32 792 controls of European ancestry to determine the 
most likely combination of stroke subtypes affected for loci with published 
genome-wide stroke associations, using model selection. Cases were 
subtyped under 2 commonly used stroke classification systems, TOAST 
(Trial of Org 10172 Acute Stroke Treatment) and causative classification of 
stroke. All individuals had genotypes imputed to the Haplotype Reference 
Consortium 1.1 Panel.
RESULTS: Sixteen loci were considered for analysis. Seven loci influenced 
both hemorrhagic and ischemic stroke, 3 of which influenced ischemic 
and hemorrhagic subtypes under both TOAST and causative classification 
of stroke. Under causative classification of stroke, 4 loci influenced both 
small vessel stroke and intracerebral hemorrhage. An EDNRA locus 
demonstrated opposing effects on ischemic and hemorrhagic stroke. No 
loci were predicted to influence all stroke subtypes in the same direction, 
and only one locus (12q24) was predicted to influence all ischemic stroke 
subtypes.
CONCLUSIONS: Heterogeneity in the influence of stroke-associated 
loci on stroke subtypes is pervasive, reflecting differing causal pathways. 
However, overlap exists between hemorrhagic and ischemic stroke, which 
may reflect shared pathobiology predisposing to small vessel arteriopathy. 
Stroke is a complex, heterogeneous disorder requiring tailored analytic 
strategies to decipher genetic mechanisms.
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The burden of stroke on global healthcare and soci-ety is substantial; it is consistently one of the lead-ing causes of death and disability worldwide,1 and 
a major cause of cognitive impairment and dementia. 
However, there exist significant gaps in our understand-
ing of the pathological processes that underlie the dis-
ease. In recent years, GWAS (genome-wide association 
studies) have made considerable advances in identifying 
genetic components underlying complex traits, in many 
cases identifying novel disease pathways and treatments.2
Characterizing the genetic component to stroke has 
been challenging, in part due to clinical heterogeneity, 
with at least 3 distinct major pathological processes (car-
dioembolism, large artery atherosclerosis, and small ves-
sel disease) underlying the majority of ischemic strokes; 
and 2 processes underlying the majority of intracerebral 
hemorrhagic stroke (small vessel disease and cerebral 
amyloid angiopathy).3,4 However, recent GWAS have 
made considerable advances; 32 independent genome-
wide significant loci were identified in the MEGASTROKE 
project.5 The majority of these loci were identified as 
being associated with inclusive all stroke or ischemic 
stroke categories, rather than specific stroke subtypes. 
This is in part due to study design, with much larger 
samples for these broader categories and only a fraction 
of stroke cases having detailed phenotyping. Indeed, 
this finding is in contrast to earlier studies that identified 
loci such as HDAC9, PITX2 as being associated with spe-
cific subtypes.6,7 To interpret genetic risk associations in 
the context of biological mechanisms, a pertinent ques-
tion is whether the newly identified stroke-associated 
loci truly confer risk across all stroke subtypes, or wheth-
er isolated or combinations of subtypes are affected. At 
least one of the novel variants (on chromosome 1q22) 
shows association with both ischemic and hemorrhagic 
stroke, which might point to some shared mechanisms 
underlying these clinically distinct entities, which have 
thus far been separated in genetic studies.
Conventional approaches to GWAS, which employ 
within study analysis and subsequent meta-analysis 
across groups, do not enable detailed model compari-
son across different subgroups. In this analysis, we used 
multinomial logistic regression on well-characterized 
subjects with individual-level data to investigate the 
association of all identified genetic GWAS loci to date 
with all stroke subtypes (cardioembolic [CES], large 
artery stroke [LAS], small vessel stroke [SVS], and intra-
cerebral hemorrhage [ICH]), determining the most 
likely combination of stroke subtypes affected at each 
locus. We performed our analysis using 2 established 
subtyping approaches: the TOAST (Trial of Org 10172 
in Acute Stroke Treatment),8 and causative classifica-
tion of stroke (CCS) system,9 to provide a comprehen-
sive account of these loci across available classification 
systems. Our overall aim was to evaluate genetic loci 
identified in previous studies using stroke data sets with 
well-defined phenotyping to determine if subtype spec-
ificity or cross-subtype associations could be identified.
METHODS
To minimize the possibility of unintentionally sharing informa-
tion that can be used to reidentify private information, a sub-
set of the data generated for this study are available from the 
database of Genotypes and Phenotypes (dbGaP) and can be 
accessed at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000615.v1.p1. Trinculo v0.96 is 
available from https://sourceforge.net/projects/trinculo/files/. 
MEGASTROKE data is available from http://megastroke.org. 
All contributing studies were approved by institutional review 
committees. All research participants contributing clinical 
and genetic samples for analysis in this study provided writ-
ten informed consent. Full methods are provided in the Data 
Supplement.
RESULTS
After QC, there were up to 16 664 cases and 32 792 con-
trols remaining for analysis (Table 1). In the merged data 
set, a binomial genome-wide analysis of all cases against 
controls had a genomic inflation λ=1.09, while the link-
age disequilibrium score regression (LDSCORE) intercept 
value was 1.04,10 suggesting that the majority of inflation 
was due to polygenicity and that any bias introduced by 
merging the data sets was minimal.
Sixteen loci contained SNPs with log (Bayes factors) 
of at least 4 in analyses of alternative stroke classifica-
tion systems: TOAST or CCS system (causative system). 
We took these 16 loci forward for further model selec-
tion. Plots for all loci under each classification system 
are provided in Figures I through XVI in the Data Sup-
plement. For each of the 16 loci, we identified the most 
likely combination of associated phenotypes at each 
locus (Figure 1, Table 2) based on model selection. A 
comparison of odds ratios (ORs) for analyzed loci from 
Table 1. Sample Sizes
TOAST CCS
N
Age 
(mean 
[SD])
Male 
(%) N
Age 
(mean 
[SD])
Male 
(%)
CES 3847 72 (14) 49 2826 75 (12) 44
LAS 2803 68 (12) 65 2204 67 (12) 62
SVS 3976 64 (13) 62 3093 63 (13) 62
UND 4085 65 (16) 54 4013 65 (15) 53
ICH 1953 71 (13) 53 1953 71 (13) 53
Controls 32 792 62 (17) 46 28 052 62 (17) 48
Age available not available for controls from WTCCC2 studies.
CCS indicates causative classification of stroke system (causative system); 
CES, cardioembolic stroke; ICH, intracerebral hemorrhage; LAS, large artery 
atherosclerotic stroke; SVS, small artery occlusion stroke; TOAST, Trial of Org 
10172 Acute Stroke Treatment Classification System; and UND, stroke of 
undetermined cause.
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MEGASTROKE and the most recent ICH publication 
with those from our analysis showed high consistency 
(r2=0.95, Figure XVII in the Data Supplement) despite 
slightly differing samples. Linkage Disequilibrium (LD) 
values between our lead and previously published SNPs 
for the 16 loci in this analysis are provided in Table I in 
the Data Supplement.
For 7 loci, the combination of phenotypes most likely 
to be influenced by the lead genetic variant at the loci 
included both ischemic and hemorrhagic stroke sub-
types. These are shown in Figure 2. At four of these loci: 
EDNRA, 1q22, MMP12, and SH3PXD2A, the ischemic 
subtype included SVS, highlighting shared mechanisms 
underlying ICH, and SVS, likely through predisposition 
to cerebral small vessel disease. At the EDNRA locus, 
the direction of association for ICH was opposite to 
that for LAS and SVS, pointing to contrasting influence 
on ischemic and hemorrhagic stroke risk. We explored 
whether ICH-associated loci were specific to deep or 
lobar ICH. As in previous reports,11,12 associations at 
1q22 and COL4A2 appear to be specific to deep ICH, 
with no effect in lobar ICH. For other regions, the evi-
dence for specificity was more equivocal (Table II in the 
Data Supplement).
For 4 loci HDAC9, PITX2, ZFHX3, and ANK2, only one 
phenotype was affected by the lead variant (Figure 1, 
Figures X, XIII, XVI, and V in the Data Supplement) in 
the most likely configuration across all classification 
systems. Several other loci 9p21, 12q24, 16q24, and 
FOXF2 were associated with only one phenotype under 
particular classification systems but did not show con-
sistency across TOAST and CCS (Figures II, III, IV, and 
IX in the Data Supplement). For TSPAN2, which was 
previously identified as being associated with LAS,13 
the best-fit model also included CES under CCS, albeit 
with a much weaker effect than LAS (rs17479660; CES, 
OR=1.08; LAS, OR=1.19 under CCS). Echoing previous 
results, the locus showed much stronger significance 
under CCS classifications than under TOAST (Figure XV 
in the Data Supplement).
For COL4A2, the strongest association found under 
TOAST was for rs9515201. The most likely model con-
tained ICH (OR=1.14) and SVS (OR=1.13), consistent 
with findings from previous analyses.12 However, under 
CCS an alternate SNP, rs1927349, was the strongest 
associated. No association with SVS was observed, and 
a weak association with CES was observed instead. 
Reasons for this discrepancy between CCS and TOAST 
are not immediately clear, but nonoverlapping samples 
between the 2 classification systems are a likely factor.
The mean (SD) number of stroke subtypes affected 
at each locus were 1.88 (0.89) under TOAST and 1.69 
(0.87) under CCS. Under CCS, the most common com-
bination of affected subtypes was SVS and ICH (4 loci).
Figure 1. Stroke subtypes in best fitting 
model at each locus, for Causative Classification 
System (CCS) and TOAST (Trial of Org 10172 
Acute Stroke Treatment Classification System) 
classification systems, with size weighted by 
association odds ratio. Results are presented 
for the 16 loci showing log (Bayes factor) >4 
in causative classification system of stroke 
(CCS) or TOAST analyses. Classification/locus 
combinations in gray indicate that the locus did 
not reach log (Bayes factor) >4 in that analysis. 
CES indicates cardioembolic stroke; LAS, large 
artery stroke; SVS, small vessel stroke; and ICH, 
intracerebral hemorrhage.
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DISCUSSION
We performed a large-scale genetic analysis, charac-
terizing the effects of established stroke risk loci with 
ischemic and hemorrhagic stroke subtypes in up to 
16 664 cases and 32 792 controls. Our main findings 
are 2-fold. First, for the vast majority of loci studied, 
multiple but never all stroke subtypes were affected 
Table 2. Lead SNPs, Association Statistics, and Affected Stroke 
Subtypes for Each Locus
Locus
Lead SNP 
[Best 
Model] log OR (SE) log BF
Subtypes in 
Best-Fitting 
Model
1q22 rs2758603 
[CCS]
0.10 (0.03) SVS 4.0 SVS and ICH
0.11 (0.05) ICH
0.02 (0.03) CES
0.07 (0.03) UNK
0.07 (0.03) LAS
9p21 rs1412830 
[TOAST]
0.08 (0.03) SVS 5.7 LAS and SVS
0.07 (0.04) ICH
−0.01 (0.03) CES
0.03 (0.03) UNK
0.14 (0.03) LAS
12q24 rs10774624 
[TOAST]
0.10 (0.03) SVS 5.8 CE, LAS, and 
SVS
−0.03 (0.05) ICH
0.07 (0.03) CES
0.07 (0.03) UNK
0.10 (0.03) LAS
16q24 rs12445022 
[TOAST]
0.13 (0.03) SVS 5.8 LAS and SVS
0.05 (0.05) ICH
−0.01 (0.03) CES
0.07 (0.03) UNK
0.07 (0.03) LAS
ANK2 rs149538932 
[CCS]
0.07 (0.03) SVS 6.4 ICH
0.18 (0.05) ICH
0.04 (0.03) CES
0.08 (0.03) UNK
0.02 (0.03) LAS
CDK6 rs4272 [CCS] 0.05 (0.04) SVS 8.5 LAS and ICH
0.10 (0.05) ICH
0.07 (0.03) CES
0.12 (0.03) UNK
0.14 (0.04) LAS
COL4A2 rs1927349 
[CCS]
−0.02 (0.03) SVS 5.0 CES and ICH
0.16 (0.05) ICH
0.08 (0.03) CES
0.04 (0.03) UNK
0.02 (0.03) LAS
EDNRA rs17612742 
[CCS]
0.09 (0.04) SVS 10.5 CES, LAS, SVS, 
and ICH
−0.23 (0.06) ICH
−0.08 (0.04) CES
−0.00 (0.04) UNK
0.13 (0.04) LAS
FOXF2 rs11242678 
[CCS]
0.13 (0.03) SVS 7.4 LAS and SVS
−0.05 (0.05) ICH
0.07 (0.03) CES
0.09 (0.03) UNK
0.09 (0.04) LAS
(Continued )
HDAC9 rs2107595 
[TOAST]
0.04 (0.04) SVS 19.2 LAS
−0.08 (0.06) ICH
0.05 (0.04) CES
0.06 (0.03) UNK
0.27 (0.04) LAS
LINC01492 rs10990643 
[TOAST]
−0.02 (0.04) SVS 4.1 LAS and ICH
0.12 (0.06) ICH
0.03 (0.04) CES
0.01 (0.03) UNK
0.17 (0.04) LAS
MMP12 rs470234 
[CCS]
0.09 (0.04) SVS 8.7 LAS, SVS, and 
ICH
0.17 (0.06) ICH
0.04 (0.04) CES
0.03 (0.04) UNK
0.20 (0.04) LAS
PITX2 rs2723334 
[TOAST]
0.0 (0.04) SVS 48.0 CES
0.08 (0.06) ICH
0.29 (0.04) CES
0.03 (0.03) UNK
−0.03 (0.04) LAS
SH3PXD2A rs10883922 
[CCS]
0.13 (0.03) SVS 6.0 SVS and ICH
0.16 (0.05) ICH
0.02 (0.03) CES
0.02 (0.03) UNK
0.04 (0.03) LAS
TSPAN2 rs7537796 
[CCS]
−0.05 (0.03) SVS 6.8 CES and LAS
−0.06 (0.05) ICH
0.06 (0.03) CES
−0.02 (0.03) UNK
0.14 (0.03) LAS
ZFHX3 rs67329386 
[TOAST]
−0.02 (0.03) SVS 13.8 CES
−0.05 (0.05) ICH
0.20 (0.03) CES
0.02 (0.03) UNK
0.00 (0.03) LAS
CCS indicates causative classification system of stroke; CES, cardioembolic 
stroke; ICH, intracerebral hemorrhage; LAS, large artery stroke; UNK, Stroke 
of undetermined cause; log BF, log transform of Bayes factor; log OR, log 
transform of odds ratio; SVS, small vessel stroke; TOAST, Trial of Org 10172 
Acute Stroke Treatment Classification System.
Table 2. Continued
Locus
Lead SNP 
[Best 
Model] log OR (SE) log BF
Subtypes in 
Best-Fitting 
Model
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at the locus. Only one locus (12q24) was assumed to 
influence all ischemic stroke subtypes. This indicates 
that although these loci were identified in analyses of 
inclusive stroke phenotypes, in the main, their effects 
are specific to particular combinations of stroke sub-
types. The mean number of subtypes affected was 
1.88 for TOAST and 1.69 for CCS classification sys-
tems. Notable exceptions were the PITX2 and ZFHX3 
loci, which were associated with cardioembolic stroke 
most likely through atrial fibrillation (for which they are 
well-established loci14), and HDAC9 which is associ-
ated with large vessel stroke. Under TOAST, the FOXF2 
locus was associated solely with SVS. However, under 
CCS, LAS was also implicated. For CCS, the 9p21 locus 
was predicted to influence only LAS. However, under 
TOAST, SVS was also implicated. Our analyses sug-
gest that ANK2 confers risk of stroke predominantly 
through its influence on ICH. We were unable to iden-
tify any loci for which the most likely model included 
all stroke phenotypes in the same direction and only 
Figure 2. Local plots showing associations with regions conferring risk of ischemic and hemorrhagic stroke and odds ratios for all stroke subtypes.  
A, 1q22 region; (B) Endothelin receptor type A region; (C) Cyclin dependent kinase 6 CDK6 region; (D) Long Intergenic Non-Protein Coding RNA 1492 region; 
(E) SH3 And PX Domains 2A region; (F) Matrix metalloproteinase 12 region; and (G) COL4A2 collagen type IV alpha 2 chain region. Results are presented for the 
classification system in which the locus showed strongest significance. Stroke subtypes in bold indicate those included in the best fitting model and, therefore, 
predicted to be influenced by the lead genetic variant, based on Bayesian model selection. CCS indicates causative classification of stroke system; CES, cardioem-
bolic stroke; LAS, large artery atherosclerotic stroke; SVS, small vessel stroke; ICH, intracerebral hemorrhage; TOAST, Trial of Org 10172 Acute Stroke Treatment 
Classification System; and UND, stroke of undetermined cause.
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one (12q24) which for which the most likely model 
included all ischemic stroke subtypes.
Second, we find evidence that several loci influence 
both hemorrhagic and ischemic stroke. This was evident 
for 7 loci in total (1q22, COL4A2, EDNRA, LINC01492, 
MMP12, SH3PXD2A, and CDK6). Under CCS, 4 loci 
(SH3PXD2A, MMP12, EDNRA, and 1q22) influenced 
both SVS and ICH, highlighting shared mechanisms 
underlying small vessel disease. Previous GWAS analy-
ses have tended to separate ischemic and hemorrhagic 
stroke on the basis of presumed differing causes. Our 
results suggest that including hemorrhagic alongside 
ischemic stroke in multiphenotype analyses will provide 
further insights.
For one locus EDNRA (endothelin receptor type A), 
the association with ICH was in the opposite direction 
to the ischemic stroke subtypes, suggesting opposing 
risk mechanisms. This locus has previously been associ-
ated with a variety of vascular phenotypes, including 
coronary artery disease, carotid plaques, and peripheral 
arterial disease (all in concordant direction with isch-
emic stroke), as well as intracranial aneurysm (in con-
cordant direction with intracerebral hemorrhage).15–18 
The locus has also been associated with migraine in 
candidate gene studies,19 but this has not been vali-
dated in GWA studies and is likely a false positive.20 ETA 
(EDNRA encodes the type A receptor) for ET-1 (endo-
thelin-1), a potent vasoconstrictor with proinflamma-
tory effects. ETA-specific antagonists increase nitric 
oxide-mediated endothelium-dependent relaxation, 
reduce ET-1 levels and inhibit atherosclerosis in mice,21 
suggesting that higher levels of ETA are proatherogenic: 
consistent with the observation that higher ETA levels 
are observed in atherosclerotic plaques.22 Based on this, 
one might expect the EDNRA risk variant (C allele of 
rs17612742 in this study) to lead to increased risk of 
ischemic stroke through elevated ETA levels. Indeed, in 
GWA studies of intracranial aneurysm, the susceptibil-
ity variant (in LD with the T allele of rs17612742 in our 
study) was shown to result in higher transcription factor 
binding affinity, likely resulting in repression of the tran-
scriptional activity of EDNRA.17 This suggests that car-
riers of the C allele have lower levels of EDNRA, which 
consequently higher ET-1 levels and greater suscepti-
bility to atherosclerosis. The reason why for carriers of 
T allele lower levels of ETA might promote intracranial 
aneurysm and intracerebral hemorrhage is not imme-
diately obvious, but several mechanisms are possible. 
Levels of ET-1 have been linked to vascular remodel-
ing, an important process underlying ICH and IA23,24; 
subtle changes in this process induced by altered avail-
ability of ETA is one such mechanism. Deep ICH and 
ischemic SVS arise due to the same arteriopathy that 
arises in the deep perforating arteries of the brain. The 
EDNRA variant in this study points to a mechanism that 
influences whether the resulting pathology is ischemic 
or hemorrhagic and as such warrants further detailed 
investigation.
Some loci were notably more significant when phe-
notyped using CCS; SH3XPD2A, MMP12, TSPAN2, 
FOXF2, and EDNRA, which might point to CCS having 
greater accuracy and, therefore, utility in stroke GWA 
studies. However, the opposite was also true for others: 
16q24, HDAC9. We note that some differences may 
be due to the fact that not all individuals were sub-
typed under both CCS and TOAST; the TOAST cohort 
was a least 20% larger. A detailed discussion of the 
relative merits of TOAST and CCS is beyond the scope 
of this article, but our results highlight that the impor-
tance of collecting individual phenotypic qualities that 
make up the etiologic subtypes in genetic studies of 
stroke so that associated loci can be more systemati-
cally examined.
Our study has several strengths. The data set was a 
large stroke population, including intracerebral hemor-
rhage and ischemic stroke cases, the majority of which 
were subtyped under both TOAST and CCS. We had full 
access to genotype-level data enabling us full control 
over all analyses. The implementation of a multinomial 
regression approach enabled us to systematically assess 
which stroke subtypes were likely to be affected at 
each locus, which would not be formally possible under 
standard binomial regression approaches which analyze 
each stroke subtype separately. Ultimately, mechanistic 
studies will be required to determine the influence of 
associated genetic variants, but analyses such as this 
have utility in directing the focus and model systems 
suitable for such follow-up studies.
Similarly, there are limitations. We present results 
for the most likely combination of stroke phenotypes 
affected at each locus: the best-fitting model. We had 
limited statistical power to determine with statistical 
certainty that this was the correct model; significantly 
larger samples would be required to achieve this. One 
consequence of this is that there remains the poten-
tial that some associations are due to random varia-
tion rather than true biological differences. It would, 
therefore, be prudent to treat some of the findings 
here as preliminary until confirmed in larger samples. 
Due to the challenges of performing these analyses 
across different ancestry populations, and as we only 
had a small number of non-European ancestry ICH 
cases available which could lead to overfitting, we 
performed analyses in European populations only. The 
results can, therefore, not be generalized to all popu-
lations. Repeating these analyses once sufficient data 
from other ancestral groups are available should be 
highly prioritized to ensure advancements in the field 
are made for all ancestral groups. In all analyses we 
assume there is a single causal variant at the locus, 
which may not be true in all cases. Our analyses are 
based on use of a default prior, which has been used 
D
ow
nloaded from
 http://ahajournals.org by on July 18, 2019
Traylor et al; Subtype Specificity of Stroke Genetic Loci
Circ Genom Precis Med. 2019;12:e002338. DOI: 10.1161/CIRCGEN.118.002338 July 2019 313
in many genetic studies. An alternative is to derive an 
empirical prior from associated genetic loci. As more 
loci are identified as being associated with stroke, this 
will become a more realistic possibility and should be 
explored in future analyses.
CONCLUSIONS
Our findings suggest that although large scale genome-
wide studies of broad all stroke or all ischemic stroke 
phenotypes are able to identify multiple associations; 
it should not be assumed that such associations con-
fer risk equally across stroke subtypes. Heterogeneity 
in the influence of genetic variants on different stroke 
subtypes is the norm, not the exception. The multino-
mial regression approach used here provided insights 
into the etiological stroke subtypes most prominently 
influenced by genetic variants at these loci—a prereq-
uisite to decide on the most appropriate model systems 
to choose for further mechanistic studies. Stroke is a 
complex, heterogeneous disorder: our findings high-
light the ongoing need for large, well-phenotyped case 
collections and tailored analytic strategies to decipher 
the underlying genetic mechanisms.
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